Evotec is to acquire Kinaxo Biotechnologies, a German drug discovery services company, in a cash and stock deal worth around €16 million.
Evotec will pay €3 million in cash and issue about 2.6 million shares of its stock to Kinaxo.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?